Publication - Progress report

New Medicines Reviews 2013

Published: 3 May 2013
Part of:
Health and social care
ISBN:
9781782565604

Reports on the role of SMC & Review of IPTR & ADTC

91 page PDF

324.6 kB

91 page PDF

324.6 kB

Contents
New Medicines Reviews 2013
Footnotes

91 page PDF

324.6 kB

Footnotes

1. Although there is no formal, or internationally agreed, definition of an ultra-orphan disease, the National Institute for Health and Clinical Excellence (NICE) uses the term for conditions occurring in less than 1000 people in the UK (equating to less than 100 people in Scotland).

2. Novel medicines in this context mean a new chemical entity where the mode of action is different to that of existing medicines.

3. http://www.scottish.parliament.uk/parliamentarybusiness/CurrentCommittees/52064.aspx

4. http://www.scottish.parliament.uk/parliamentarybusiness/CurrentCommittees/29831.aspx

5. Patient Access Schemes represent a discount arrangement to facilitate the entry of new medicines and managed by National Services Scotland (NSS) through assessment of the scheme via the Patient Access Scheme Assessment Group (PASAG).

6. http://www.scotland.gov.uk/News/Releases/2013/01/medicines-fund14012013


Contact

Email: VERONICA MOFFAT